Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate reported a strong growth in Q4 and full-year 2022 financial results, with revenues of $675.3 million in Q4, marking a 20.4% increase, and total revenues of $2.66 billion for the full year, up 41.7%. The increase in revenue was largely attributed to the acquisition of ProQuest. However, a significant non-cash goodwill impairment led to a net loss of $4.04 billion for the year. Despite challenges, adjusted EBITDA rose to $1.11 billion, indicating robust operational performance. The company is set to discuss its growth plans during an Investor Day on March 9, 2023.
Clarivate Plc (NYSE:CLVT) will ring the opening bell at the New York Stock Exchange on March 6, 2023. The company announced its Investor Day conference for March 9, 2023, which will be streamed live due to limited in-person capacity. CEO Jonathan Gear highlighted the company’s progress in transforming the business and enhancing shareholder value. The opening bell will take place at 9:30 a.m. ET on March 6, and the Investor Day will run from 9:00 a.m. to 12:00 p.m. ET on March 9. Live streams will be available on both the NYSE and Clarivate's investor relations website.
On February 22, 2023, Clarivate Plc (NYSE: CLVT) and the KAIST Innovation Strategy and Policy Institute released a report analyzing the global innovation landscape of the AI chip industry. The report highlights a shift from mass-produced chips to specialized, mission-oriented processors due to rising demand for efficient data processing. Key findings indicate that the U.S. and Mainland China dominate AI chip patents, with the U.S. exhibiting higher patent quality. The report emphasizes collaboration between universities and industry for R&D innovation, proposing strategies for the future AI chip market.
On February 9, 2023, Clarivate (NYSE:CLVT) announced the integration of the Preprint Citation Index™ into the Web of Science™ platform. This new feature allows researchers to access nearly two million preprints from various reputable repositories such as arXiv, bioRxiv, and chemRxiv alongside peer-reviewed content. The index facilitates quicker research processes by linking preprints to final articles and displaying them on researchers' profiles. The initiative aims to enhance scientific collaboration and speed up advancements in global research challenges, further establishing Clarivate as a leader in academic publishing.
On February 7, 2023, Clarivate Plc (NYSE: CLVT) announced that it will release its financial results for the fourth quarter and full year 2022 on March 1, 2023, before market opening. Detailed financial information will be available on their investor website. A conference call and webcast will occur on the same day at 9:00 AM Eastern Time to discuss the results. Interested participants can access the live audio broadcast or join through the webcast link provided. Additionally, an audio replay will be available after the call until March 15, 2023.
Clarivate Plc (NYSE:CLVT) released a special investigation by BioWorld, examining the evolving understanding of obesity and the impact of new weight loss drugs. With an expected one billion people facing obesity by 2030, novel therapeutics, including GLP-1R agonists, offer promising alternatives to traditional weight loss methods. The report discusses the cultural complexities surrounding obesity, the limitations of using weight as a health indicator, and highlights that fitness may be more closely associated with health than weight itself. The findings suggest a shift in the medical community's perception of weight loss and overall health.
Clarivate Plc (NYSE:CLVT) recently released its 2023 Drugs to Watch report, marking its tenth anniversary. The report predicts over 70 drugs that may transform treatment for various conditions, including HIV and Parkinson's disease. Notably, 15 late-stage experimental treatments are expected to surpass $1 billion in annual sales within five years. The report also highlights promising developments in Mainland China, especially in oncology, with nine drugs forecasted to reach blockbuster status by 2030, supported by healthcare reforms under Healthy China 2030.
On January 3, 2023, Clarivate Plc (NYSE: CLVT) collaborated with the Chinese Academy of Sciences to release the 'Research Fronts 2022' report, detailing 165 significant research areas in sciences and social sciences. The report identifies 110 'hot' and 55 'emerging' fronts, with over a third related to COVID-19, focusing on topics like vaccine effectiveness. Utilizing the Essential Science Indicators database, the report provides insights into scientific trends, showcasing the US as the leader in research, while highlighting a narrowing gap with China.
Clarivate (NYSE: CLVT) announced the adoption of a Tax Benefits Preservation Plan to safeguard its U.S. net operating loss carryforwards exceeding $1 billion as of September 30, 2022. This plan aims to prevent an 'ownership change' that could limit its ability to utilize these tax benefits. The plan will expire on October 31, 2023, unless terminated earlier. Shareholders will receive one preferred share purchase right for each ordinary share, activating if any party acquires 4.9% or more of shares. The plan is similar to those by other companies with significant NOLs.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
